

08th February, 2018

✓ The Dy. General Manager (Listing Dept.)
BSE Limited.,
Corporate Relationship Dept.,
1st Floor, New Trading Ring,
P. J. Towers, Dalal Street, Fort,
Mumbai - 400 001
(BSE Scrip Code: 500420)

~~The Manager – Listing Dept.,
National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G. Block,
Bandra - Kurla Complex, Bandra (E),
Mumbai – 400 051
(NSE Scrip Code: TORNTPHARM)~~

Dear Sir,

Sub.: Presentation to analysts on un-audited Consolidated Financial Results for the quarter and nine months ended 31st December, 2017

The presentation on un-audited Consolidated Financial Results for the quarter and nine months ended 31st December, 2017 to be made to analysts is enclosed for your records.

Thanking you,

Yours Sincerely,

For TORRENT PHARMACEUTICALS LIMITED



MAHESH AGRAWAL
VP (LEGAL) & COMPANY SECRETARY

Encl.: As above



Q3 & YTD Dec 2017-18



Consolidated Revenues for Q3 2017-18

(` Crore)

Particulars	Q3 1718	Q3 1617	Gr%
India	586	503	17%
US	266	310	-14%
Brazil	194	159	22%
Germany	241	203	19%
Other	131	121	9%
Others (Incl contract Mfg.)	59	147	-60%
Total	1,477	1,443	2%



Consolidated Revenues for YTD Dec 2017-18

(` Crore)

Particulars	YTD Dec 1718	YTD Dec 1617	Gr%
India	1,657	1,509	10%
US	793	1,065	-26%
Brazil	495	484	2%
Germany	664	577	15%
Other	390	361	8%
Others (Incl contract Mfg.)	281	427	-34%
Total	4,280	4,423	-3%

